Industry leaders and academics are urging Bangladesh’s pharmaceutical companies to deepen ties with universities and research centres to stay competitive after leaving least developed country status, and that appeal is shaping a practical plan to boost jobs, exports and higher-value medicine making. Strong partnerships would give drug makers access to trained graduates, shared laboratory space, and fresh research ideas while giving students hands-on training, internships and clear career paths so talent stays in the country. Companies would benefit from joint labs for formulation, analytical testing and small scale production that lower early costs and speed new product design. Universities would gain by seeing their students work on real problems, improving curriculum and building skills in biotechnology, quality control and regulatory science. Practical actions can start small: cofounded research projects, short industry courses for faculty, student internships inside factories, and incubators that help start-ups test prototypes. Better data sharing and regular advisory boards will help align research with industry needs so projects focus on marketable products and export rules. A clear system for intellectual property and fair licensing will encourage firms and academics to share results without fear of losing rights, and simple legal templates can make partnerships faster. Training in good manufacturing practice, clinical trial design and quality assurance should be run together by companies and universities so new staff meet global standards from day one. The government and finance bodies can boost the change with careful incentives such as matching research grants, tax breaks for joint labs, and seed funds for biotech start-ups that create local jobs. Public hospitals and clinics can take part by offering spaces for clinical research and testing, which speeds approvals and helps build trust in new medicines. International links with foreign labs and companies can bring technology transfer and help local teams learn modern methods in a safe, tested way. Over time, the sector can move into higher value chains like monoclonal antibodies, biosimilars and complex injectables that bring higher margins and steady export demand. All this can raise wages for technicians, create new science careers and support local suppliers for packaging, cold chain and logistics. The approach also helps meet quality and safety rules that buyers abroad require, making it easier to win new contracts and WHO prequalification when needed. With steady, practical steps and honest cooperation, pharma-academia partnerships can turn research into real products, build a skilled workforce and make the country’s medicine industry more resilient, export ready and able to offer better care at home. Stakeholders say early pilots and clear policies will show quick wins and lay the groundwork for long-term growth. Success will depend on steady funding, transparent rules, regular industry reviews, and sustained training so breakthroughs reach patients and markets quickly and strengthen public confidence nationwide.
